|
|
| Type |
Symposium |
| Area |
Biomacromolecules and Protein Engineering |
| Room No. |
403호 |
| Time |
FRI 09:40-: |
| Code |
BIO2-2 |
| Subject |
Next-generation antibody platform technology |
| Authors |
김용성
아주대학교 응용화학생명공학과, Korea |
| Abstract |
The use of monoclonal antibodies (mAbs), which specifically bind to target molecules with high affinity, is of interest for many pharmaceutical and industrial applications. As of January 2017, more than 48 mAbs have been clinically approved in worldwide for diverse indications, mainly cancers and autoimmune/inflammatory diseases. However, the clinical efficacy of mAbs approved for solid-tumor cancer therapy is relatively low as a single agent showing response rates of 8% - 18% even for the qualified patients for particular mAb. Also, market competition becomes very high due to already-marked and coming-soon biosimilar mAbs. Therefore there are great needs for the development of innovative mAbs against new targets and next-generation mAbs with superior profiles to current mAbs. Next-generation antibody will show greater clinical efficacy, reduced side-effects, and more convenient administrations. Further innovative antibody technology which can target cytosolic proteins is required to expand the target space of therapeutic antibodies.
In this talk, I will discuss our effort to develop proprietary platform technology for next generation antibody therapeutics, including bispecific antibody, tumor tissue penetrating antibody, and cell-penetrating antibody for targeting of intracellular molecules.
|
| E-mail |
kimys@ajou.ac.kr |
|
119th General Meeting of the KCS